InsuJet Distribution Expands Across Canada
NuGen Medical Devices (TSXV: NGMD) announces expanded distribution of its InsuJet™ needle-free insulin delivery device across Canada following Health Canada approval and nationwide introduction in November 2024.
The device is now available through major pharmacy retailers including London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, and McKesson Canada. New partnerships with Kohl & Frisch and a national retail partner will begin mid-April 2025.
The company's Canadian distributor, Sol-Millennium, has partnered with MyRxCare and Greenshield Canada for pharmacy adjudication and educational support. Additionally, they continue collaboration with I Challenge Diabetes, whose CEO Chris Jarvis promotes the technology nationwide. Sol-Millennium is actively participating in various healthcare conferences throughout 2025 to engage with healthcare professionals and promote the benefits of InsuJet™.
NuGen Medical Devices (TSXV: NGMD) annuncia l'espansione della distribuzione del suo dispositivo per la somministrazione di insulina senza ago InsuJet™ in tutto il Canada, a seguito dell'approvazione da parte di Health Canada e del lancio nazionale previsto per novembre 2024.
Il dispositivo è ora disponibile presso i principali rivenditori farmaceutici, tra cui London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart e McKesson Canada. Nuove collaborazioni con Kohl & Frisch e un partner commerciale nazionale inizieranno a metà aprile 2025.
Il distributore canadese dell'azienda, Sol-Millennium, ha stretto una partnership con MyRxCare e Greenshield Canada per la gestione delle autorizzazioni in farmacia e il supporto educativo. Inoltre, continua la collaborazione con I Challenge Diabetes, il cui CEO Chris Jarvis promuove la tecnologia a livello nazionale. Sol-Millennium parteciperà attivamente a diverse conferenze sanitarie nel 2025 per coinvolgere i professionisti del settore e promuovere i vantaggi di InsuJet™.
NuGen Medical Devices (TSXV: NGMD) anuncia la expansión de la distribución de su dispositivo para la administración de insulina sin agujas InsuJet™ en todo Canadá, tras la aprobación de Health Canada y su lanzamiento nacional en noviembre de 2024.
El dispositivo ya está disponible a través de los principales minoristas farmacéuticos, incluyendo London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart y McKesson Canada. Nuevas alianzas con Kohl & Frisch y un socio minorista nacional comenzarán a mediados de abril de 2025.
El distribuidor canadiense de la empresa, Sol-Millennium, se ha asociado con MyRxCare y Greenshield Canada para la adjudicación en farmacias y el apoyo educativo. Además, continúan colaborando con I Challenge Diabetes, cuyo CEO Chris Jarvis promueve la tecnología a nivel nacional. Sol-Millennium participará activamente en diversas conferencias de salud durante 2025 para conectar con profesionales sanitarios y promover los beneficios de InsuJet™.
NuGen Medical Devices (TSXV: NGMD)는 2024년 11월 Health Canada 승인과 전국 출시 이후 캐나다 전역으로 InsuJet™ 바늘 없는 인슐린 전달 장치의 유통을 확대한다고 발표했습니다.
이 장치는 현재 London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, McKesson Canada 등 주요 약국 소매업체를 통해 구매할 수 있습니다. Kohl & Frisch 및 전국 소매 파트너와의 새로운 협력은 2025년 4월 중순부터 시작될 예정입니다.
회사의 캐나다 유통업체인 Sol-Millennium은 약국 심사 및 교육 지원을 위해 MyRxCare 및 Greenshield Canada와 협력하고 있습니다. 또한 CEO 크리스 자비스가 전국적으로 이 기술을 홍보하는 I Challenge Diabetes와의 협력도 계속 이어가고 있습니다. Sol-Millennium은 2025년 동안 다양한 의료 컨퍼런스에 적극 참여하여 의료 전문가들과 소통하고 InsuJet™의 장점을 홍보할 계획입니다.
NuGen Medical Devices (TSXV : NGMD) annonce l’élargissement de la distribution de son dispositif d’administration d’insuline sans aiguille InsuJet™ à travers le Canada, suite à l’approbation de Santé Canada et au lancement national prévu en novembre 2024.
Le dispositif est désormais disponible chez les principaux distributeurs pharmaceutiques, notamment London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart et McKesson Canada. De nouveaux partenariats avec Kohl & Frisch et un partenaire commercial national débuteront à la mi-avril 2025.
Le distributeur canadien de la société, Sol-Millennium, s’est associé à MyRxCare et Greenshield Canada pour la gestion des remboursements en pharmacie et le soutien pédagogique. Par ailleurs, la collaboration avec I Challenge Diabetes, dont le PDG Chris Jarvis fait la promotion de la technologie à l’échelle nationale, se poursuit. Sol-Millennium participera activement à diverses conférences médicales tout au long de 2025 pour échanger avec les professionnels de santé et promouvoir les avantages d’InsuJet™.
NuGen Medical Devices (TSXV: NGMD) kündigt die erweiterte Distribution seines nadelfreien Insulinabgabegeräts InsuJet™ in ganz Kanada an, nachdem Health Canada die Zulassung erteilt und die landesweite Einführung im November 2024 erfolgt ist.
Das Gerät ist nun über große Apothekenhändler wie London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart und McKesson Canada erhältlich. Neue Partnerschaften mit Kohl & Frisch sowie einem nationalen Einzelhandelspartner beginnen Mitte April 2025.
Der kanadische Vertriebspartner des Unternehmens, Sol-Millennium, arbeitet mit MyRxCare und Greenshield Canada für die Apothekenabrechnung und Schulungsunterstützung zusammen. Zudem wird die Zusammenarbeit mit I Challenge Diabetes fortgesetzt, dessen CEO Chris Jarvis die Technologie landesweit fördert. Sol-Millennium nimmt 2025 aktiv an verschiedenen Gesundheitskonferenzen teil, um mit Fachkräften in Kontakt zu treten und die Vorteile von InsuJet™ zu bewerben.
- Significant retail expansion through major Canadian pharmacy chains
- New distribution partnership with Kohl & Frisch
- Integration with pharmacy benefit managers MyRxCare and Greenshield Canada
- Strategic partnership with I Challenge Diabetes for promotional support
- None.
Toronto, Ontario--(Newsfile Corp. - April 24, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is please to report that distribution of The InsuJet™ will be expanded with increased availability across Canada connecting alongside health professionals.
"Following its Health Canada approval and our nationwide introduction at World Diabetes Day held on November 14th, 2024, The InsuJet™ device is already making a measurable difference in diabetes care across Canada" commented Liang Lin, CEO of Nugen. "We have a wonderful testimonial, called Lilly's story that is both meaningful to the Company from a product adoption perspective while also illustrating the strong impact we are having on patient care."
Lilly's story. A teenager from Northern Canada diagnosed with diabetes at a young age, switching to InsuJet.
Click here to view Lilly's story: Why Lilly Anna loves InsuJet™
Expanding Availability Across Canada
In the first quarter of 2025, InsuJet™ made its way into Canadian pharmacy retailers and distributors, including London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, and McKesson Canada. The newest distribution partner, Kohl & Frisch, and a national retail partner will begin offering InsuJet™ in their pharmacies by mid-April.
To further support accessibility and education, NuGen's exclusive distributor for Canada, Sol-Millennium has onboarded pharmacy adjudication partner MyRxCare and Greenshield Canada. These partnerships will help Canadian pharmacy retailers deliver education aimed at identifying Canadians with diabetes who could benefit from needle-free insulin administration.
Additionally, Sol-Millennium continues partnership with I Challenge Diabetes, a Canadian non-profit organization dedicated to supporting families living with diabetes. Their CEO and founder, Chris Jarvis-T1 Gold Medal Rower for Canada- will continue to promote and raise awareness of this innovative technology across the country.
Connecting with Healthcare Professionals
Further, Sol-Millennium will be attending several key pharmacy and healthcare conferences across Canada in 2025, and keep engaging with healthcare professionals: endocrinologists, primary care physicians, pharmacists, Certified Diabetes Educators (CDEs), and researchers. These events provide a platform to showcase the InsuJet™ device and highlight its benefits to a wide clinical audience.
Sol-Millennium also look forward to connecting directly with Canadian families living with diabetes, promoting a needle-free future, and gathering valuable feedback and testimonial opportunities. These engagements align with Sol-Millennium's mission of advancing patient care for those living with diabetes as well as future commitment to having InsuJet™ added to the Canadian Diabetes Guidelines.
Recent Past Conferences:
Diabetes Simplify (Toronto, ON - March 1st)
Vendor Theatre (Toronto, ON - March 6th)
Durham Care Diabetes Symposium (Oshawa, ON - April 5th)
Familiprix (Quebec - April 11th -12th)
Upcoming Conferences:
Pharma Choice (Calgary, AB - April 25th - 26th)
2025 Pharmacy Trade Show - Pattison Food Group (Edmonton, AB - April 26th)
Pharmasave (Vancouver, BC - April 29th - 30th)
2025 Diabetes Canada/CSEM Professional Conference (Toronto, ON - November 26th - 28th)
About Sol-Millennium Medical Group
Sol-Millennium Medical Group is a vertically integrated manufacturer of medical devices. With global operations and a commitment to deliver advanced, patient-friendly healthcare technologies, Sol-Millennium Medical partners with healthcare providers to improve outcomes and build a healthier tomorrow for all.
About NuGen
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously. The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.
For further information, please visit:
Websites: www.insujet.com, and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/
For further information, please contact:
Liang Lin, Chief Executive Officer
+1 (833) 285-2666
llin@nugenmd.com
Investor Relations:
Richard Buzbuzian
(647) 501-3290
Richard@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249688
FAQ
Where can I buy InsuJet needle-free insulin device (NGMDF) in Canada?
When did InsuJet (NGMDF) receive Health Canada approval?
What pharmacy benefits providers support InsuJet (NGMDF) in Canada?
Which diabetes conferences is InsuJet (NGMDF) attending in 2025?
